LIFECORE BIOMEDICAL, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable
LIFECORE BIOMEDICAL, INC. (LFCR) had Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable of 548.69 thousand shares as of 2018-05-27, per its 10-K filed 2018-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions · last filed 2018-08-09
- 2018-05-27: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 548.69K shares.
- 2017-05-28: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 314.09K shares.
- 2016-05-29: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 418.47K shares.
- 2015-05-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 663.67K shares.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable |
|---|---|
| 2018-05-27 | 548.69K shares 10-K · filed 2018-08-09 |
| 2017-05-28 | 314.09K shares 10-K/A · filed 2018-03-15 |
| 2016-05-29 | 418.47K shares 10-K · filed 2016-08-01 |
| 2015-05-31 | 663.67K shares 10-K · filed 2015-07-31 |
| 2014-05-25 | 852.92K shares 10-K · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |